"Mother's Anguish: The Fate of Her Daughter's CF Drug Funding Hangs in the Balance"
Georgia Burchell, the mother of a 15-month-old baby with cystic fibrosis, is anxiously waiting for the NHS to decide whether to fund drugs that could double her daughter's life expectancy. The drugs, Orkambi, Symkevi, and Kaftrio, are considered "lifesaving" and could provide a normal life for her daughter. However, the cost of treatment, which exceeds £100,000 per patient per year, may make it unaffordable for the NHS. While her daughter is due to start Orkambi soon, she cannot begin Kaftrio until she is two years old. The final decision is expected to be announced next year.